TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25530057
Drug: Injection at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection at a seeking current of <0.5 mA
Study: 24473591
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine - ma zi ren wan (MZRW) 7.5 g bid
Study: 14522478
Drug: Clopidogrel pretreatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel pretreatment (300 mg before PCI)
Study: 22805313
Drug: Low-dose Korean
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Korean red ginseng (3 g/day)
Study: 22805313
Drug: High-dose Korean
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Korean red ginseng (6 g/day)
Study: 22805313
Drug: KRG supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: KRG supplementation (both doses)
Study: 19194969
Drug: Trans-resveratrol 25
Normalized name: trans-resveratrol 3-β-glucoside
DrugBank: Polydatin (DB11263)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trans-resveratrol 25 mg, six times/day for thirteen doses
Study: 19194969
Drug: Trans-resveratrol 50
Normalized name: trans-resveratrol 3-β-glucoside
DrugBank: Polydatin (DB11263)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trans-resveratrol 50 mg, six times/day for thirteen doses
Study: 19194969
Drug: Trans-resveratrol 100
Normalized name: trans-resveratrol 3-β-glucoside
DrugBank: Polydatin (DB11263)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trans-resveratrol 100 mg, six times/day for thirteen doses
Study: 19194969
Drug: Trans-resveratrol 150
Normalized name: trans-resveratrol 3-β-glucoside
DrugBank: Polydatin (DB11263)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trans-resveratrol 150 mg, six times/day for thirteen doses
Study: 9951927
Drug: Adjuvant locoregional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant locoregional chemoimmunotherapy (Gemcitabine 1 gm/m2, Carboplatin 200 mg/m2, Mitoxantrone 0.2 g/kg bw, IL-2, gamma-IFN)
Study: 7924365
Drug: Medications containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medications containing glucose
Study: 31582622
Drug: LDL-C lowering
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-C lowering drug therapy (primarily statins)
Study: 31582622
Drug: No LDL-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: No LDL-C lowering drug therapy
Study: 14648073
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1000 mg calcium carbonate for 6 weeks)
Study: 7871090
Drug: alpha-2 adrenoceptor
Normalized name: (2S)-alpha-2-Amino-4-methylvaleric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-2 adrenoceptor antagonist (high dose)
Study: 28978818
Drug: G1-DES (First-Generation
Approvals — FDA: no, EMA: no, PMDA: no
Description: G1-DES (First-Generation Drug-Eluting Stents)
Study: 28978818
Drug: G2-DES (Second-Generation
Approvals — FDA: no, EMA: no, PMDA: no
Description: G2-DES (Second-Generation Drug-Eluting Stents)
Study: 19320897
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure instillation therapy
Study: 19320897
Drug: Standard surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard surgical debridement with gentamicin polymethylmethacrylate beads and long‐term intravenous antibiotics (Control)
Study: 10813543
Drug: Mobilization with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobilization with cyclophosphamide (CY) plus G-CSF
Study: 10813543
Drug: Mobilization with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobilization with CY plus GM-CSF (8 days) followed by G-CSF
Study: 8925804
Drug: High-protein meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein meal (80 gm total protein: 4.1 g phenylalanine, 8.2 g leucine, 4.2 g isoleucine, 52 g carbohydrate, 9 g fat)
Study: 1516877
Drug: Remefa S
Normalized name: S-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remefa S (glycyrrhizinic acid), administered three times a week for 12 months
Study: 6148361
Drug: ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine (300 mg/day)
Study: 6148361
Drug: cimetidine (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: cimetidine (1200 mg/day)
Study: 28407661
Drug: Saxagliptin 5
Normalized name: sAXagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin 5 mg per day for 12 weeks
Study: 28407661
Drug: Metformin 1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1,500 mg per day for 12 weeks
Study: 16025958
Drug: Compound Duzhong
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Duzhong Jiangu granule (CDJG)
Study: 16025958
Drug: Zhuanggu Guanjie
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhuanggu Guanjie pill (ZGP)
Study: 14504154
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural analgesia (TEA) with bupivacaine (0.25% during operation, 0.125% after operation) and fentanyl (2 microg ml(‐1))
Study: 31608608
Drug: Postoperative antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative antibiotics prescribed for 44% of the extractions
Study: 31608608
Drug: No postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No postoperative antibiotics prescribed
Study: 27846058
Drug: Investigational hexavalent
Normalized name: botulinum neurotoxin B immune FAB2
DrugBank: Equine Botulinum Neurotoxin B Immune FAB2 (DB13903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational hexavalent vaccine (HV)
Study: 19765505
Drug: Participants compared
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants compared to NSW adult daily smokers
Study: 17577495
Drug: Tramadol preoperative,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol preoperative, 100 mg IM 1 hour before surgery (group A)
Study: 17577495
Drug: Tramadol postoperative,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol postoperative, 100 mg IM immediately after surgery (group B)
Study: 11740320
Drug: RRV-tetravalent vaccine
Normalized name: dengue virus live antigen, CYD serotype 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRV-tetravalent vaccine
Study: 9973803
Drug: Oxatomide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxatomide (1 mg/kg/day) in one evening dose
Study: 9973803
Drug: Oxatomide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxatomide (1 mg/kg/day) divided into two administrations
Study: 9973803
Drug: Oxatomide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxatomide (2 mg/kg/day) after dosage increase
Study: 29445912
Drug: Pan-fried beef
Normalized name: Beef
DrugBank: Beef (DB10509)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pan-fried beef steak (270±20 g)
Study: 29445912
Drug: Sous-vide beef
Normalized name: Beef
DrugBank: Beef (DB10509)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sous-vide beef steak (270±20 g)
Study: 8918410
Drug: Bicalutamide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide (50 mg once daily) plus LHRH analogue therapy (goserelin acetate 3.6 mg every 28 days or leuprolide acetate 7.5 mg every 28 days)
Study: 8918410
Drug: Flutamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (250 mg three times daily) plus LHRH analogue therapy (goserelin acetate 3.6 mg every 28 days or leuprolide acetate 7.5 mg every 28 days)
Study: 6211327
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (0.16 mg by pressurized inhaler; 1 mg nebulized)
Study: 6211327
Drug: Salbutamol (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (0.8 mg by pressurized inhaler; 5 mg nebulized)
Study: 30393868
Drug: Low-Intensity Pulsed
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Intensity Pulsed Ultrasound (LIPUS) therapy applied bilaterally for 20 minutes daily for the first 10 days and thereafter at least 3 times per week until complete mandibular advancement was achieved.
Study: 30393868
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no LIPUS therapy).
Study: 23236345
Drug: Weekly standardized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly standardized motivational text message
Study: 11394244
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E supplementation (300 mg alpha‐tocopherol daily)
Study: 9608882
Drug: Fast Melting
Normalized name: CVS Motion Sickness Fast Melting 25mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast Melting Tablet (FMT)
Study: 9608882
Drug: Sugar Coated
Normalized name: TIOPRONIN 100 mg ORAL TABLET, SUGAR COATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar Coated Tablets (SCT)
Study: 8015023
Drug: 10 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micrograms of recombinant yeast‐derived HBV vaccine
Study: 8015023
Drug: 20 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 micrograms of recombinant yeast‐derived HBV vaccine
Study: 3050522
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 mg twice daily)
Study: 3050522
Drug: Heparin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (1000 units per hour by intravenous infusion)
Study: 3050522
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus Heparin
Study: 28574158
Drug: Whitening microneedle
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whitening microneedle patch
Study: 18289446
Drug: Intraoperative intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative intravenous tramadol 2 mg kg(‐1)
Study: 18289446
Drug: Placebo (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (30 mL saline)
Study: 16494982
Drug: Ground linseeds
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ground linseeds (20 g/d) for 2 months
Study: 12559660
Drug: Chromium picolinate
Normalized name: Chromium Picolinate
DrugBank: Chromium picolinate (DB11255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chromium picolinate (600 micro g for 8 weeks)
Study: 11038077
Drug: rhuMAb CD18
Normalized name: rhuMAb 2H7
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: rhuMAb CD18 (2 mg/kg)
Study: 11038077
Drug: rhuMAb CD18
Normalized name: rhuMAb 2H7
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: rhuMAb CD18 (1 mg/kg)
Study: 11038077
Drug: rhuMAb CD18
Normalized name: rhuMAb 2H7
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: rhuMAb CD18 (0.5 mg/kg)
Study: 9075510
Drug: Painstop (paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Painstop (paracetamol 12 mg, codeine 0.5 mg, promethazine 0.65 mg per 1.0 ml, dosage 1.0 ml/kg)
Study: 29266485
Drug: One-stage ridge
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-stage ridge augmentation with resorbable membrane (M+)
Study: 29266485
Drug: One-stage ridge
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-stage ridge augmentation without resorbable membrane (M-)
Study: 22246619
Drug: 400‐mg EGCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400‐mg EGCG as PPE
Study: 22246619
Drug: 800‐mg EGCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800‐mg EGCG as PPE
Study: 20163376
Drug: PF-03491390 (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-03491390 (5, 25 or 50 mg) orally twice daily for up to 12 weeks
Study: 17905607
Drug: Resilon after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resilon after retreatment (no further treatment)
Study: 12108617
Drug: Synthetic human
Normalized name: Synthetic human secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synthetic human secretin (single dose)
Study: 2136991
Drug: Low-energy gallium-arsenide
Normalized name: GALLIUM ARSENIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy gallium-arsenide laser treatment
Study: 31773372
Drug: Placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy with a laser device that did not make active pulses
Study: 29178842
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of pepsin and amino acid hydrochloride taken as tablets three times daily for 6 weeks
Study: 29178842
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of pepsin and amino acid hydrochloride
Study: 18593092
Drug: Evidence-based resources
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based resources for dentists (e.g., journals, online resources like PubMed and Cochrane Collaboration)
Study: 17201610
Drug: Quetiapine (400-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (400-600 mg/day)
Study: 17201610
Drug: Divalproex (serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divalproex (serum level 80-120 microg/mL)
Study: 12749423
Drug: Fixed group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed group (GnRH antagonist starting on day 6 of stimulation)
Study: 12749423
Drug: Flexible group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible group (GnRH antagonist starting when a follicle of > or = 15 mm was present)
Study: 29910054
Drug: Adaptive servoventilation
Normalized name: ADAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive servoventilation (ASV) + Optimal Medical Therapy (OMT)
Study: 20456213
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg vardenafil orodispersible tablet (ODT)
Study: 10617943
Drug: Encapsulated fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encapsulated fish oil (1.45 g eicosapentaenoic acid and 1.55 g docosahexaenoic acid/d) for 4 weeks
Study: 9382759
Drug: Pseudomonas aeruginosa
Normalized name: Pseudomonas aeruginosa
DrugBank: Pseudomonas aeruginosa (DB19284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine
Study: 1554923
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg/d during five months
Study: 3754234
Drug: piperazinedione 9
Normalized name: 2,5-piperazinedione
Approvals — FDA: no, EMA: no, PMDA: no
Description: piperazinedione 9 mg/m2 iv every 3 weeks
Study: 3754234
Drug: cisplatin 50
Normalized name: cisplatin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cisplatin 50 mg/m2 iv every 3 weeks
Study: 30816148
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of a combination of polyphenolic extracts from Lippia citriodora L. and Hibiscus sabdariffa L. (LC-HS)
Study: 25238909
Drug: Leucovorin 0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucovorin 0 mg/m2
Study: 25238909
Drug: Leucovorin 60
Normalized name: leucovorin 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucovorin 60 mg/m2
Study: 25238909
Drug: Leucovorin 200
Normalized name: leucovorin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucovorin 200 mg/m2
Study: 25238909
Drug: Leucovorin 500
Normalized name: leucovorin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucovorin 500 mg/m2
Study: 22729297
Drug: Dexamethasone (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (6 mg/ml)
Study: 22729297
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline 1 ml)
Study: 16574937
Drug: 1018 ISS
Normalized name: 1018 ISS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1018 ISS (36 mg by nebulization weekly for 4 weeks)
Study: 14606080
Drug: Capsule oxymatrine
Normalized name: Oxymatrine
DrugBank: Oxymatrine (DB16276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule oxymatrine
Study: 14606080
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of oxymatrine
Study: 8881618
Drug: Alfentanil 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 1 mg
Study: 8881618
Drug: Lignocaine 40
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine 40 mg
Study: 31074689
Drug: Total IgG
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total IgG levels in MI subjects with MACE (24.9 mg/mL)
Study: 31074689
Drug: Total IgG
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total IgG levels in controls (18.4 mg/mL)
Study: 31074689
Drug: C-reactive protein
Normalized name: C-reactive protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-reactive protein (CRP) levels in MI subjects with MACE (1.1 mg/mL)
Study: 31074689
Drug: C-reactive protein
Normalized name: C-reactive protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-reactive protein (CRP) levels in controls (1.9 mg/mL)
Study: 30081016
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogens (CEE 0.625 mg/day)
Study: 30081016
Drug: Oral CEE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral CEE + medroxyprogesterone acetate (CEE 0.625 mg/day + MPA 2.5 mg/day)
Study: 20551965
Drug: Salmon (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmon (3 x 150 g/week, 2.1 g LC n-3 PUFA per day)
Study: 20551965
Drug: Cod (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cod (3 x 150 g/week, 0.3 g LC n-3 PUFA per day)
Study: 20551965
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil capsules (1.3 g LC n-3 PUFA per day)
Study: 8905437
Drug: Cisapride 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 0.2 mg/kg body weight, 30 min prior to measurement of GCTT
Study: 1678921
Drug: Terazosin 5
Normalized name: terazosin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin 5 mg
Study: 1678921
Drug: Terazosin 10
Normalized name: terazosin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin 10 to 40 mg
Study: 1678921
Drug: Terazosin 1
Normalized name: terazosin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin 1 to 5 mg
Study: 7048339
Drug: 0.2% dithranol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% dithranol and urea cream
Study: 7048339
Drug: 0.1% dithranol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% dithranol and urea cream
Study: 30861163
Drug: Bovine colostrum
Normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine colostrum supplement during 4 weeks of induction treatment
Study: 30861163
Drug: Bovine colostrum
Normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine colostrum supplement
Study: 30861163
Drug: Placebo supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo supplement during 4 weeks of induction treatment
Study: 12770854
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (20 ppm NO)
Study: 9022539
Drug: Cafestol (61-64
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cafestol (61-64 mg/d)
Study: 9022539
Drug: Cafestol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cafestol plus kahweol (cafestol 60 mg/d and kahweol 48-54 mg/d)
Study: 3899033
Drug: Piracetam (1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam (1600 mg 3 times a day)
Study: 3899033
Drug: Pentoxifylline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (400 mg 3 times a day)
Study: 3899033
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of piracetam and pentoxifylline
Study: 26004290
Drug: Monthly information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly information bulletins and phone calls (comparison group)
Study: 20951543
Drug: Exposure Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure Therapy Only (EXP)
Study: 18469642
Drug: Intermittent intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent intravenous pantoprazole (40 mg q24 hour; 40 mg q12 hour; 80 mg q24 hour; 80 mg q12 hour; 80 mg q8 hour)
Study: 18469642
Drug: Continuous cimetidine
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous cimetidine infusion (300 mg bolus; 50 mg/h)
Study: 18469642
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (pantoprazole and cimetidine)
Study: 16531895
Drug: Carbohydrate and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate and protein hydrolysate (CHO-PRO: 0.8 g.kg.h carbohydrate and 0.4 g.kg.h protein)
Study: 16531895
Drug: Carbohydrate, protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate, protein hydrolysate, and free leucine (CHO-PRO-LEU: 0.8 g.kg.h carbohydrate, 0.4 g.kg.h protein, and 0.1 g.kg.h leucine)
Study: 16531895
Drug: Carbohydrate (CHO:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate (CHO: 0.8 g.kg.h)
Study: 3173919
Drug: Vaginal bromocriptine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal bromocriptine 2.5 mg
Study: 3173919
Drug: Vaginal bromocriptine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal bromocriptine 5.0 mg
Study: 3173919
Drug: Vaginal bromocriptine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal bromocriptine 7.5 mg
Study: 3173919
Drug: Oral bromocriptine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bromocriptine 2.5 mg
Study: 25802434
Drug: Mass test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass test and treatment (MTAT) intervention; three rounds; details on dosage and duration not specified.
Study: 20352370
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg magnesium per kilogram body weight (Group 1 - sedentary controls)
Study: 20352370
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg magnesium per kilogram body weight (Group 2 - tae kwon do athletes)
Study: 20352370
Drug: No magnesium
Normalized name: DPBS 1X, NO CALCIUM, NO MAGNESIUM
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No magnesium supplements (Group 3 - tae kwon do athletes)